Esophageal Cancer Market Expected to Experience Accelerated Growth and Market Evolution by 2036 - DelveInsight

DelveInsight's "Esophageal Cancer Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of the Esophageal Cancer, historical and forecasted epidemiology as well as the Esophageal Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Esophageal Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Esophageal Cancer Market Forecast
https://www.delveinsight.com/sample-request/esophageal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Esophageal Cancer Market Report:
• In 2025, the esophageal cancer market size was valued at approximately USD 1,300 million, and it is projected to grow at a compound annual growth rate (CAGR) of around 6.0% from 2025 to 2036, indicating steady expansion driven by evolving treatment approaches and increasing therapeutic advancements.
• In November 2025, Pembrolizumab (KEYTRUDA) in combination with chemotherapy showed sustained long-term survival benefit in advanced esophageal cancer, with 5-year follow-up data from the Phase III KEYNOTE-590 study confirming improved overall survival and progression-free survival versus chemotherapy alone.
• In June 2025, The FDA approved PD-L1 IHC 22C3 pharmDx (Code SK006) as a companion diagnostic test for patients with esophageal or gastroesophageal junction (GEJ) carcinoma who may be candidates for pembrolizumab therapy. The diagnostic assay is designed to detect PD-L1 expression in tumors, aiding clinicians in selecting appropriate patients for immunotherapy treatment.
• In April 2025, Researchers showcased emerging therapeutic approaches for esophageal cancer, including innovative immunotherapy combinations, the development of novel biomarkers, and advancements in perioperative treatment strategies. Particular emphasis was placed on broadening the application of PD-1 inhibitors and enhancing treatment responses across both early-stage and metastatic disease settings.
• In March 2025, Tislelizumab (TEVIMBRA) received FDA approval in combination with chemotherapy for first-line treatment of unresectable or metastatic esophageal squamous cell carcinoma (ESCC) with PD-L1 expression, marking an important addition to frontline immunotherapy options.
• In March 2025, The FDA approved tislelizumab-jsgr (Tevimbra) in combination with platinum-based chemotherapy as a first-line treatment for adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1. This approval further broadens the use of immunotherapy in the frontline management of ESCC.
• In January 2025, Nivolumab (OPDIVO) plus chemotherapy continued to demonstrate durable overall survival benefit in patients with advanced gastric, gastroesophageal junction, and esophageal cancers, based on 5-year follow-up results from the Phase III CheckMate-649 trial, reinforcing its role in first-line treatment.
• According to DelveInsight's estimates, the total incident cases of esophageal cancer in the 7MM were approximately 79,000 in 2025.
• It has been observed that the incidence of non-squamous cell esophageal cancer is higher (~14,000) as compared to squamous cell esophageal cancer (~8,000) in the United States.
• It is observed that esophageal cancer is found to be more incident in males (~17,000) as compared to females (~5,000) in the United States.
• Among EU4 and the UK, Germany accounted for the highest number of glioma cases, followed by France, whereas Spain had the lowest number of cases in 2025.
• In 2025, among total-stage specific cases, distant esophageal cancer was the most incident followed by regional stage-specific esophageal cancer in Germany.
• In the United States, among all the age groups, ≥65 years accounted for the highest number of esophageal cancer cases, i.e., around ~14,000, in 2025, followed by the age-group 45-65 years (~8,000).
• Key Esophageal Cancer Companies: Eli Lilly and Company, Bayer, Zymeworks, Jazz Pharmaceuticals, Amgen, Jazz Pharmaceuticals, Zymeworks, BeiGene, AstraZeneca, Symphogen, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Exelixis, Bayer, BeiGene, Lyell Immunopharma, Sichuan Baili Pharmaceutical, AP Biosciences, and others
• Key Esophageal Cancer Therapies: Entrectinib (ROZLYTREK), Larotrectinib (VITRAKVI), Tislelizumab (TEVIMBRA), Durvalumab (IMFINZI), Zanidatamab, Lenvatinib (LENVIMA), CYRAMZA (ramucirumab), VITRAKVI (larotrectinib), Zanidatamab, Bemarituzumab, Zanidatamab, Tislelizumab, XB002, LGK974, Abemaciclib, ladiratuzumab vedotin, ATRC-101, SGN-PDL1V, RO7247669, THOR-707, Letetresgene Autoleucel, TNO155, Anlotinib Hydrochloride, Larotinib, SCT-I10A, Serplulimab, CS1001, Camrelizumab, Durvalumab, Sym021, Spartalizumab, Sym022, Sym023, Regorafenib, S095033, INCB099318, RO7121661, KF-0210, SCT200, Ramucirumab, Cabozantinib, JAB-3068, Onivyde, JAB-3312, SGN-B6A, RAPA-201,Ociperlimab, SI B001,Apatinib, and others
• The Esophageal Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Esophageal Cancer pipeline products will significantly revolutionize the Esophageal Cancer market dynamics.

Esophageal Cancer Overview
Esophageal cancer refers to the development of cancerous cells in the esophagus, the tube that carries food from the mouth to the stomach. The esophagus is part of the digestive system and is located between the throat (pharynx) and the stomach. Esophageal cancer can occur when the cells lining the esophagus undergo abnormal changes and start growing uncontrollably.

Get a Free sample for the Esophageal Cancer Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/esophageal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Esophageal Cancer Epidemiology
The Esophageal Cancer epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Esophageal Cancer Epidemiology Segmentation:
The Esophageal Cancer market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:
• Total Diagnosed Incident Cases of Esophageal Cancer
• Histology-specific Cases of Esophageal Cancer
• Gender-specific Cases of Esophageal Cancer
• Age-specific Cases of Esophageal Cancer
• Mutation-specific Cases of Esophageal Cancer
• Total Stage-specific Cases of Esophageal Cancer
• Line wise Treated Cases of Esophageal Cancer

Download the report to understand which factors are driving Esophageal Cancer epidemiology trends @ Esophageal Cancer Epidemiology Forecast
https://www.delveinsight.com/sample-request/esophageal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Esophageal Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Esophageal Cancer market or expected to get launched during the study period. The analysis covers Esophageal Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Esophageal Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Esophageal Cancer Therapies and Key Companies
• Entrectinib (ROZLYTREK): Eli Lilly and Company
• Larotrectinib (VITRAKVI): Bayer
• Tislelizumab (TEVIMBRA): BeiGene
• Durvalumab (IMFINZI): AstraZeneca
• Zanidatamab: Zymeworks/Jazz Pharmaceuticals
• Lenvatinib (LENVIMA): Merck/Eisai
• CYRAMZA (ramucirumab): Eli Lilly and Company
• VITRAKVI (larotrectinib): Bayer
• Zanidatamab: Zymeworks/Jazz Pharmaceuticals
• Bemarituzumab: Amgen
• Zanidatamab: Jazz Pharmaceuticals/Zymeworks
• Tislelizumab: BeiGene
• Durvalumab: Celgene/MedImmune
• Tucatinib: Seagen
• M1231: Merck KGaA
• APX 005M: Apexigen
• Erdafitinib: Janssen Research & Development, LLC
• Margetuximab: MacroGenics
• AN-0025: Adlai Nortye

Discover more about therapies set to grab major Esophageal Cancer market share @ Esophageal Cancer Treatment Landscape
https://www.delveinsight.com/sample-request/esophageal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Esophageal Cancer Market Drivers
• Rising incidence of esophageal cancer, particularly adenocarcinoma and squamous cell carcinoma, is increasing demand for effective treatment options.
• Growing adoption of immunotherapies, targeted therapies, and precision medicine approaches is improving patient outcomes and expanding the treatment landscape.
• Advancements in diagnostic technologies and biomarker testing are enabling earlier detection and personalized treatment strategies.
• Increased investment in oncology research and clinical trials is accelerating the development of innovative therapies.

Esophageal Cancer Market Barriers
• Late-stage diagnosis in many patients limits treatment effectiveness and contributes to poor survival rates.
• High costs associated with advanced therapies, including immunotherapies and targeted treatments, can restrict patient access.
• Treatment-related toxicities and adverse events may impact patient adherence and quality of life.
• Complex disease biology and tumor heterogeneity pose challenges for drug development and treatment optimization.

Scope of the Esophageal Cancer Market Report
• Study Period: 2022-2036
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Esophageal Cancer Companies: Eli Lilly and Company, Bayer, Zymeworks, Jazz Pharmaceuticals, Amgen, AstraZeneca, Symphogen, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Exelixis, Bayer, BeiGene, Lyell Immunopharma, Sichuan Baili Pharmaceutical, AP Biosciences, and others
• Key Esophageal Cancer Therapies: Entrectinib (ROZLYTREK), Larotrectinib (VITRAKVI), Tislelizumab (TEVIMBRA), Durvalumab (IMFINZI), Zanidatamab, Lenvatinib (LENVIMA), CYRAMZA (ramucirumab), VITRAKVI (larotrectinib), Zanidatamab, Bemarituzumab, Zanidatamab, Tislelizumab, XB002, LGK974, Abemaciclib, ladiratuzumab vedotin, ATRC-101, SGN-PDL1V, RO7247669, THOR-707, Letetresgene Autoleucel, TNO155, Anlotinib Hydrochloride, Larotinib, SCT-I10A, Serplulimab, CS1001, Camrelizumab, Durvalumab, Sym021, Spartalizumab, Sym022, Sym023, Regorafenib, S095033, INCB099318, RO7121661, KF-0210, SCT200, Ramucirumab, Cabozantinib, JAB-3068, Onivyde, JAB-3312, SGN-B6A, RAPA-201,Ociperlimab, SI B001,Apatinib, and others
• Esophageal Cancer Therapeutic Assessment: Esophageal Cancer current marketed and Esophageal Cancer emerging therapies
• Esophageal Cancer Market Dynamics: Esophageal Cancer market drivers and Esophageal Cancer market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Esophageal Cancer Unmet Needs, KOL's views, Analyst's views, Esophageal Cancer Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.